Next Article in Journal
Gastric Juice Expression of Th-17 and T-Reg Related Cytokines in Scleroderma Esophageal Involvement
Next Article in Special Issue
Proteostasis Disturbances and Inflammation in Neurodegenerative Diseases
Previous Article in Journal
HNSCC: Tumour Antigens and Their Targeting by Immunotherapy
Previous Article in Special Issue
CUL4-DDB1-CRBN E3 Ubiquitin Ligase Regulates Proteostasis of ClC-2 Chloride Channels: Implication for Aldosteronism and Leukodystrophy
Open AccessArticle

Evaluating Serum Heat Shock Protein Levels as Novel Biomarkers for Atrial Fibrillation

1
Department of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije University, 1081HV Amsterdam, The Netherlands
2
Department of Cardiology, Erasmus MC, 3000CA Rotterdam, The Netherlands
3
Netherlands Heart Institute, 3511EP Utrecht, The Netherlands
*
Author to whom correspondence should be addressed.
These authors contributed equally to this paper.
These authors contributed equally to this paper.
Cells 2020, 9(9), 2105; https://doi.org/10.3390/cells9092105
Received: 23 July 2020 / Revised: 9 September 2020 / Accepted: 14 September 2020 / Published: 16 September 2020
(This article belongs to the Special Issue Proteostasis in Aging and Disease)
Background: Staging of atrial fibrillation (AF) is essential to understanding disease progression and the accompanied increase in therapy failure. Blood-based heat shock protein (HSP) levels may enable staging of AF and the identification of patients with higher risk for AF recurrence after treatment. Objective: This study evaluates the relationship between serum HSP levels, presence of AF, AF stage and AF recurrence following electrocardioversion (ECV) or pulmonary vein isolation (PVI). Methods: To determine HSP27, HSP70, cardiovascular (cv)HSP and HSP60 levels, serum samples were collected from control patients without AF and patients with paroxysmal atrial fibrillation (PAF), persistent (PeAF) and longstanding persistent (LSPeAF) AF, presenting for ECV or PVI, prior to intervention and at 3-, 6- and 12-months post-PVI. Results: The study population (n = 297) consisted of 98 control and 199 AF patients admitted for ECV (n = 98) or PVI (n = 101). HSP27, HSP70, cvHSP and HSP60 serum levels did not differ between patients without or with PAF, PeAF or LSPeAF. Additionally, baseline HSP levels did not correlate with AF recurrence after ECV or PVI. However, in AF patients with AF recurrence, HSP27 levels were significantly elevated post-PVI relative to baseline, compared to patients without recurrence. Conclusions: No association was observed between baseline HSP levels and the presence of AF, AF stage or AF recurrence. However, HSP27 levels were increased in serum samples of patients with AF recurrence within one year after PVI, suggesting that HSP27 levels may predict recurrence of AF after ablative therapy. View Full-Text
Keywords: atrial fibrillation; heat shock protein; electrical cardioversion; pulmonary vein isolation; biomarkers atrial fibrillation; heat shock protein; electrical cardioversion; pulmonary vein isolation; biomarkers
Show Figures

Figure 1

MDPI and ACS Style

Marion, D.M.S.; Lanters, E.A.H.; Ramos, K.S.; Li, J.; Wiersma, M.; Baks-te Bulte, L.; J. Q. M. Muskens, A.; Boersma, E.; de Groot, N.M.S.; Brundel, B.J.J.M. Evaluating Serum Heat Shock Protein Levels as Novel Biomarkers for Atrial Fibrillation. Cells 2020, 9, 2105.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop